IN8bio Announces Clinical Data From Phase 1 Trials Of INB-100 In AML And INB-200 In GBM; Receives FDA Guidance On Registrational Path For INB-100 With IND Submission Expected In Q1 2025
Portfolio Pulse from Benzinga Newsdesk
IN8bio has announced clinical data from Phase 1 trials of INB-100 in Acute Myeloid Leukemia (AML) and INB-200 in Glioblastoma Multiforme (GBM). The company has also received FDA guidance on the registrational path for INB-100, with an IND submission expected in Q1 2025. This solidifies IN8bio's position as a leader in gamma-delta T cell therapy for oncology.
August 12, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IN8bio has released positive clinical data from Phase 1 trials for INB-100 in AML and INB-200 in GBM. The company has also received FDA guidance on the registrational path for INB-100, with an IND submission expected in Q1 2025. This news strengthens IN8bio's leadership in gamma-delta T cell therapy for oncology.
The announcement of positive clinical data and FDA guidance is likely to boost investor confidence in IN8bio, potentially driving the stock price up in the short term. The expected IND submission in Q1 2025 further solidifies the company's future prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100